The approval of TEPOXX in Japan marks another significant milestone in our mission to expand access to this critical ...

SIGA Technologies (NASDAQ:SIGA) announced Thursday that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved ...

John Boadu, Director General (DG) of the State Interests and Governance Authority (SIGA), has called on the incoming ...

It’s déjà vu for Siga Technologies and its smallpox antiviral Tpoxx. At an interim analysis of a second mpox trial, the drug again missed the mark on a key measure of disease resolution.

On Thursday, the Japan Ministry of Health, Labour and Welfare approved SIGA Technologies (NASDAQ:SIGA) antiviral treatment ...

(RTTNews) - SIGA Technologies, Inc. (SIGA), Thursday announced that its tecovirimat 200 mg capsules, traded as TEPOXX, has secured regulatory approval in Japan for the treatment of smallpox, mpox, ...

The antiviral drug tecovirimat, from Siga Technologies (SIGA), did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low ...

SIGA Technologies receives Japanese approval for Tepoxx for the treatment of orthopoxviruses: New York Saturday, January 4, 2025, 12:00 Hrs [IST] SIGA Technologies, a commercial s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SIGA Technologies has gained Japanese regulatory approval for TEPOXX (tecovirimat) 200mg capsules, known as TPOXX in the US, for the treatment of smallpox, mpox and cowpox, and complications ...

Dec 10 (Reuters) - Siga Technologies' (SIGA.O), opens new tab antiviral drug did not reduce the time to lesion resolution or have an effect on pain among adults affected by the clade II strain of ...